Navigation Links
Newly Published Study Reveals Femara Improves Chances for Harder to,Treat Early Breast Cancer Relapse in Postmenopausal Women

FRIMLEY, SURREY, England, April 30, 2007 /PRNewswire-FirstCall/ --

- Femara reduces the risk of breast cancer spreading to the lungs, the brain or the bone which has a worse prognosis than when the cancer is localised to the breast

Newly published data in the May issue of Annals of Oncology, Oxford University Press show that after two years of post-surgical therapy, postmenopausal women with hormone-sensitive early breast cancer treated with Femara experienced 30 percent fewer early breast cancer recurrences at sites away from the breast (distant metastases) compared with tamoxifen(1).

The spread of breast cancer to other parts of the body means that it is extremely likely that a woman will die from the disease(2). Recurrences that occur locally, regionally, or in the opposite breast (contra-lateral) are more easily treated than those that spread far from the original tumour, and they are associated with better long-term outcomes(3,4).

In the retrospective analysis of more than 7,700 women at a median follow-up of two years, approximately 75 percent of early recurrences occurred at distant sites such as bone or vital organs. However, there were 30 percent fewer distant recurrences in the Femara group than in the tamoxifen group (87 vs. 125, respectively)(1).

Maria Leadbeater, Secondary Breast Cancer Nurse Specialist at Breast Cancer Care commented, "Breast Cancer Care speaks to women with breast cancer daily and knows that they welcome any treatment development that could help to reduce the likelihood of their cancer recurring. Having been treated for breast cancer the first time round, one of the greatest fears is that the disease might return. These findings confirm earlier results from this trial, and suggest that Femara may be a treatment option for postmenopausal women with early breast cancer that could help reduce the risk of this happening to them."

Compared wit
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
2. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
3. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
4. Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
5. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
6. ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
7. MRI Detects Cancers in the Opposite Breast of Women Newly Diagnosed with Breast Cancer
8. Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia
9. Newly Released Canadian Data Links Vaccines with Pervasive Developmental Disorder
10. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
11. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
Post Your Comments:
(Date:7/30/2015)... Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ... the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded ... the notice it received on May 21, 2015 from ... Company was below certain of the Exchange,s continued listing ... of the NYSE MKT Company Guide, due to the ...
(Date:7/30/2015)... COTTAGE, New York , July 30, 2015 /PRNewswire/ ... release of its latest report titled, "Continuous Glucose Monitoring ... - 2020". According to the report, the global continuous ... Mn in 2014 and is expected to reach US$ ... during the forecast period, 2015 to 2020. ...
(Date:7/30/2015)... MIAMI , July 30, 2015   ... latest update to UNI®, the world,s first operating ... simulators, is now available exclusively to Gaumard users. ... for recently launched Newborn Tory™ S2200, as well ... and monitoring of clinical measures such as EtCO ...
Breaking Medicine Technology:TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 2Gaumard's Latest UNI Operating System Update Adds Performance and New Functionality 3
... N.J., Jan. 18, 2011 Fenwal, Inc. of Lake ... they have signed an agreement under which Fenwal will ... blood centers, plasma centers and hospitals in the United ... such as Genesis™ blood collection mixers and monitors, RapidSeal ...
... Inc. announced today that the U.S. Food & ... clearance to market the SImmetry™ Sacroiliac Joint Fusion ... intended for treating conditions including degenerative sacroiliitis and ... System consists of a range of threaded, cannulated ...
Cached Medicine Technology:Fenwal, GenesisBPS Enter Agreement for Blood-Specialty Products 2Zyga Technology, Inc. Receives FDA 510(K) Clearance for the SImmetry™ Sacroiliac Joint Fusion System 2
(Date:7/30/2015)... ... July 31, 2015 , ... Committed to helping the next generation succeed ... members to contribute to the College’s “My Brother’s Keeper Scholarship.” The President’s signature initiative ... on track. Providing the support they need to think more broadly about their future. ...
(Date:7/30/2015)... ... July 30, 2015 , ... As more hospitals across the ... recruiting patients becomes a serious challenge. Because of growing competition, it is more ... the local community. , The team at Wound Care Advantage has ...
(Date:7/30/2015)... ... 2015 , ... OSF Healthcare System has been recognized as one ... conducted by Hospitals & Health Networks. This marks the fourth consecutive year for this ... Sisters of the Third Order of St. Francis . , Health data security and ...
(Date:7/30/2015)... ... ... The connection between a healthy head of hair and a feeling of confidence is a ... hair can have a devastating impact on the daily life of a person. From ... consequences of hair loss are not to be taken lightly. , The skilled staff at ...
(Date:7/30/2015)... York, NY (PRWEB) , ... July 30, 2015 ... ... Setria®Glutathione and Sustamine® L-Alanyl-L-Glutamine for people on the go. With no water needed, ... Recovery Chewable as a simple way to get the natural ingredients that may ...
Breaking Medicine News(10 mins):Health News:Mercy College a “My Brother’s Keeper” Community 2Health News:Mercy College a “My Brother’s Keeper” Community 3Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 2Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 3Health News:WCA Offers Shockwave; The Marketing Module for Hospital Wound Care Programs 4Health News:OSF HealthCare Named One of the Most Wired Systems 2Health News:OSF HealthCare Named One of the Most Wired Systems 3Health News:New Study Shows the Link between Hair Restoration and Healthy Self-Image 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 2Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 3Health News:Zaca Life Introduces Recovery Chewable Packets with Setria® Glutathione and Sustamine® L-Alanyl-L-Glutamine 4
... with cancer, the side effects of chemotherapy and ... drug-delivery research based on nano- and microtechnology from ... well as more effective cancer treatment. , New ... of Tel Aviv University,s Department of Biochemistry allows ...
... Perot Systems receives top ranking in Revenue Cycle Management ... -- For the second consecutive year, Perot Systems ... has received the #1 ranking in several categories of ... to the 2008 survey results, Perot Systems, Revenue ...
... A new analysis from the JUPITER study presented today ... California describes details of the stroke data according to ... adds to the primary analysis of the JUPITER study ... the risk of stroke by nearly half (48%; p=0.002), ...
... Create National Patient Registry, Increase Public Awareness of ... for Pulmonary Fibrosis (CPF) is excited to announce ... (PF) advocacy program -- the introduction of the ... in the 111th Congress. The PFREA, H.R. 1079, ...
... DALLAS, Feb. 19 Cholesterol-lowering statins, used by ... may falsely indicate thyroid problems, according to researchers ... studies, low serum TSH, and the influence of ... ."These findings could help physicians make quicker, more ...
... of Illinois reveals how a cellular protein recognizes an invading ... The research, described this week in the journal Science ... Medical Institute investigator Taekjip Ha, settles a debate over how ... viral RNA and self (or cellular) RNA. , "RIG-I ...
Cached Medicine News:Health News:New 'bubble' targets only cancer cells 2Health News:Perot Systems Ranked #1 Revenue Cycle Manager by Healthcare Providers 2Health News:Perot Systems Ranked #1 Revenue Cycle Manager by Healthcare Providers 3Health News:CRESTOR Cuts Risk of Stroke by Nearly Half in JUPITER Study 2Health News:CRESTOR Cuts Risk of Stroke by Nearly Half in JUPITER Study 3Health News:CRESTOR Cuts Risk of Stroke by Nearly Half in JUPITER Study 4Health News:Pulmonary Fibrosis Research Enhancement Act of 2009 Introduced in 111th U.S. Congress 2Health News:Pulmonary Fibrosis Research Enhancement Act of 2009 Introduced in 111th U.S. Congress 3Health News:Pulmonary Fibrosis Research Enhancement Act of 2009 Introduced in 111th U.S. Congress 4Health News:Dallas Scientists Discover Statins May Falsely Indicate Thyroid Problems 2Health News:Team learns how cellular protein detects viruses and sparks immune response 2
... pacing wire design offers reliable ... in the atrium and ventricle ... in one lead design. The ... ventricle are color-coded for easy ...
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
Medicine Products: